| Autor: |
Diamantopoulos, P. Koumbi, D. Kotsianidis, I. Pappa, V. Symeonidis, A. Galanopoulos, A. Zikos, P. Papadaki, H.A. Panayiotidis, P. Dimou, M. Hatzimichael, E. Vassilopoulos, G. Delimpasis, S. Mparmparousi, D. Papageorgiou, S. Variami, E. Kyrtsonis, M.-C. Megalakaki, A. Kotsopoulou, M. Repousis, P. Adamopoulos, I. Kontopidou, F. Christoulas, D. Kourakli, A. Tsokanas, D. Konstantinos Papoutselis, M. Kyriakakis, G. Viniou, N.-A. the Hellenic MDS study group |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Popis: |
In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised International Prognostic Scoring System (IPSS-R). To further characterize the prognostic significance of chromosome 17 abnormalities we analyzed the hematologic and prognostic characteristics of 548 adult patients with MDS treated with 5-azacytidine through the Hellenic 5-azacytidine registry and found 32 patients with a chromosome 17 abnormality (6 with i[17q], 15 with -17, 3 with add[17p] and the rest with other rarer abnormalities, mostly translocations). The presence of a chromosome 17 abnormality was correlated with poor prognostic features (high IPSS, IPSS-R, and WPSS scores) and a low overall survival rate (15.7 vs 36.4 months for patients without chromosome 17 abnormalities, Kaplan–Meier, Log Rank P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
